KPG 712
Alternative Names: KPG-712Latest Information Update: 29 Sep 2023
At a glance
- Originator Kangpu Biopharmaceuticals
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders; Inflammation
Most Recent Events
- 28 Aug 2023 Preclinical trials in Autoimmune disorders in China (unspecified route), prior to August 2023 (Kangpu Biopharmaceuticals pipeline, August 2023)
- 28 Aug 2023 Preclinical trials in Inflammation in China (unspecified route), prior to August 2023 (Kangpu Biopharmaceuticals pipeline, August 2023)